CERE vs. VKTX, ASND, LEGN, JAZZ, ITCI, ELAN, BPMC, ROIV, CYTK, and IONS
Should you be buying Cerevel Therapeutics stock or one of its competitors? The main competitors of Cerevel Therapeutics include Viking Therapeutics (VKTX), Ascendis Pharma A/S (ASND), Legend Biotech (LEGN), Jazz Pharmaceuticals (JAZZ), Intra-Cellular Therapies (ITCI), Elanco Animal Health (ELAN), Blueprint Medicines (BPMC), Roivant Sciences (ROIV), Cytokinetics (CYTK), and Ionis Pharmaceuticals (IONS). These companies are all part of the "pharmaceutical preparations" industry.
Viking Therapeutics (NASDAQ:VKTX) and Cerevel Therapeutics (NASDAQ:CERE) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, community ranking, profitability, risk, media sentiment, earnings and valuation.
In the previous week, Viking Therapeutics had 14 more articles in the media than Cerevel Therapeutics. MarketBeat recorded 22 mentions for Viking Therapeutics and 8 mentions for Cerevel Therapeutics. Viking Therapeutics' average media sentiment score of 0.80 beat Cerevel Therapeutics' score of 0.50 indicating that Cerevel Therapeutics is being referred to more favorably in the news media.
76.0% of Viking Therapeutics shares are held by institutional investors. Comparatively, 87.7% of Cerevel Therapeutics shares are held by institutional investors. 4.7% of Viking Therapeutics shares are held by insiders. Comparatively, 5.1% of Cerevel Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Viking Therapeutics has a beta of 1.12, meaning that its stock price is 12% more volatile than the S&P 500. Comparatively, Cerevel Therapeutics has a beta of 1.46, meaning that its stock price is 46% more volatile than the S&P 500.
Viking Therapeutics received 444 more outperform votes than Cerevel Therapeutics when rated by MarketBeat users. Likewise, 79.87% of users gave Viking Therapeutics an outperform vote while only 66.52% of users gave Cerevel Therapeutics an outperform vote.
Viking Therapeutics presently has a consensus price target of $112.38, indicating a potential upside of 67.72%. Cerevel Therapeutics has a consensus price target of $42.67, indicating a potential upside of 1.35%. Given Cerevel Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Viking Therapeutics is more favorable than Cerevel Therapeutics.
Cerevel Therapeutics' return on equity of -18.41% beat Viking Therapeutics' return on equity.
Summary
Viking Therapeutics beats Cerevel Therapeutics on 10 of the 14 factors compared between the two stocks.
Get Cerevel Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CERE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CERE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cerevel Therapeutics Competitors List
Related Companies and Tools
